{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:01:35Z","timestamp":1784901695006,"version":"3.55.0"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","award":["24-10849"],"award-info":[{"award-number":["24-10849"]}],"id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2026,6,5]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the use of postmarketing requirements under the FDA Amendments Act (FDAAA) and postmarketing commitments issued by the US Food and Drug Administration (FDA), for new drugs approved from 2016 to 2024, and to determine rates of study completion and changes in drug labelling resulting from these studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross sectional evaluation of postmarketing studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>All new drugs and their associated indications approved by the FDA's Center for Drug Evaluation and Research, 1 January 2016 to 31 December 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Population<\/jats:title>\n                    <jats:p>420 drugs approved by the FDA for 567 indications, associated with 913 FDAAA postmarketing requirements and 434 postmarketing commitments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Drug characteristics associated with issuance of FDAAA postmarketing requirements and issuance of postmarketing commitments, rates of study completion and on-time completion, and proportion of studies leading to changes in drug labelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      More than two thirds of drugs (n=287, 68.3%) had at least one FDAAA postmarketing requirement and 42.9% (n=180) had at least one postmarketing commitment. Indications with an orphan designation were more likely to have an FDAAA postmarketing requirement (63.3%\n                      <jats:italic>v<\/jats:italic>\n                      48.6%; absolute difference 14.7%, 95% confidence interval (CI) 6.7% to 22.8%), as were indications approved with an expedited programme (59.6%\n                      <jats:italic>v<\/jats:italic>\n                      48.1%; absolute difference 11.5%, 2.7% to 20.3%). Similarly, postmarketing commitments were more likely to be issued for indications with an orphan designation (47.0%\n                      <jats:italic>v<\/jats:italic>\n                      33.6%; absolute difference 13.4%, 5.4% to 21.4%) and those using expedited approval programmes (47.9%\n                      <jats:italic>v<\/jats:italic>\n                      23.8%; absolute difference 24.1%, 16.2% to 32.1%). Among studies due by the end of 2024, 73.4% (95% CI 69.2% to 77.3%; n=345) of FDAAA postmarketing requirements and 81.5% (76.3% to 86.1%; n=212) of postmarketing commitments were completed, although only 33.4% (29.1% to 37.9%) (n=157) and 36.2% (30.3% to 42.3%) (n=94), respectively, were completed on time. Of the 311 fulfilled FDAAA postmarketing requirement studies, 63.3% (n=197) resulted in at least one labelling change, most often in the section on use in specific populations and clinical pharmacology. Fewer postmarketing commitment studies (n=94, 49.7%) resulted in changes in drug labelling, with most changes found in the clinical pharmacology and clinical studies sections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FDAAA postmarketing requirements and postmarketing commitments are important regulatory tools for generating postapproval evidence, particularly for drugs approved with orphan designation or under expedited programmes. Although a large proportion of studies resulted in changes in drug labelling, delays in completion were common, highlighting the need to ensure effective oversight and timely study completion and reporting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjmed-2025-002307","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:05:13Z","timestamp":1784898313000},"page":"e002307","source":"Crossref","is-referenced-by-count":0,"title":["Completion and outcomes of postmarketing requirements and commitments issued by the US Food and Drug Administration for new drugs, 2016-24: cross sectional evaluation of postmarketing studies"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4385-5773","authenticated-orcid":false,"given":"Maximilian","family":"Siebert","sequence":"first","affiliation":[{"name":"Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rylee","family":"McGonigle","sequence":"additional","affiliation":[{"name":"Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA, USA"},{"name":"Computational Health Informatics Program, Boston Children\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1245-198X","authenticated-orcid":false,"given":"Alba","family":"Guti\u00e9rrez-Sacrist\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-5751","authenticated-orcid":false,"given":"Huseyin","family":"Naci","sequence":"additional","affiliation":[{"name":"Department of Health Policy, London School of Economics and Political Science, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-6668","authenticated-orcid":false,"given":"Anita K","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence T","family":"Bourgeois","sequence":"additional","affiliation":[{"name":"Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA, USA"},{"name":"Computational Health Informatics Program, Boston Children\u2019s Hospital, Boston, MA, USA"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072406050713000_5.1.e002307.1","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1313","article-title":"Extending the US Food and Drug Administration\u2019s Postmarket Authorities","volume":"4","author":"Fernandez Lynch","year":"2023","journal-title":"JAMA Health Forum"},{"key":"2026072406050713000_5.1.e002307.2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3284","article-title":"Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017","volume":"3","author":"Zhang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026072406050713000_5.1.e002307.3","unstructured":"U.S. Food and Drug Administration . Postmarketing requirements and commitments: introduction. FDA; 2024. Available: https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/postmarketing-requirements-and-commitments-introduction"},{"key":"2026072406050713000_5.1.e002307.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.5545"},{"key":"2026072406050713000_5.1.e002307.5","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12413"},{"key":"2026072406050713000_5.1.e002307.6","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration . Reports on the status of postmarketing study commitments \u2014 implementation of section 130 of the food and drug administration modernization act of 1997. 2006. Available: https:\/\/www.hhs.gov\/guidance\/document\/reports-status-postmarketing-study-commitments-implementation-section-130-food-and-drug"},{"key":"2026072406050713000_5.1.e002307.7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/17407745211005044","article-title":"US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018","volume":"18","author":"Skydel","year":"2021","journal-title":"Clin Trials"},{"key":"2026072406050713000_5.1.e002307.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1344-3","article-title":"Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis","volume":"17","author":"Wallach","year":"2019","journal-title":"BMC Med"},{"key":"2026072406050713000_5.1.e002307.9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jcph.2208","article-title":"US FDA Postmarketing Requirements and Commitments: A Systematic Assessment of Clinical Pharmacology Studies and Their Impact on US FDA Prescribing Information","volume":"63","author":"Ridge","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"2026072406050713000_5.1.e002307.10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40264-022-01152-9","article-title":"New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence","volume":"45","author":"Moneer","year":"2022","journal-title":"Drug Saf"},{"key":"2026072406050713000_5.1.e002307.11","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.0217","article-title":"Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021","volume":"4","author":"Deshmukh","year":"2023","journal-title":"JAMA Health Forum"},{"key":"2026072406050713000_5.1.e002307.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9415"},{"key":"2026072406050713000_5.1.e002307.13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2018.3416","article-title":"Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act","volume":"173","author":"Hwang","year":"2019","journal-title":"JAMA Pediatr"},{"key":"2026072406050713000_5.1.e002307.14","unstructured":"Center for Drug Evaluation and Research . Novel drug approvals at FDA. FDA; 2025. Available: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/novel-drug-approvals-fda [Accessed 13 Jun 2025]."},{"key":"2026072406050713000_5.1.e002307.15","unstructured":"U.S. Food and Drug Administration . Postmarketing studies and clinical trials\u2014implementation of section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act guidance for industry. 2021. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/postmarketing-studies-and-clinical-trials-implementation-section-505o3-federal-food-drug-and [Accessed 13 Jun 2025]."},{"key":"2026072406050713000_5.1.e002307.16","unstructured":"Food and drug administration modernization act of 1997. 1997. Available: https:\/\/www.congress.gov\/bill\/105th-congress\/senate-bill\/830\/text"},{"key":"2026072406050713000_5.1.e002307.17","unstructured":"U.S. Food and Drug Administration . Drugs@FDA: fda-approved drugs. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm [Accessed 13 Jun 2025]."},{"key":"2026072406050713000_5.1.e002307.18","unstructured":"U.S. Food and Drug Administration . Postmarketing requirements and commitments: searchable database. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/pmc\/index.cfm [Accessed 13 Jun 2025]."},{"key":"2026072406050713000_5.1.e002307.19","unstructured":"U.S. Food and Drug Administration . Postmarketing requirements and commitments: frequently asked questions (FAQ). FDA; 2024. Available: https:\/\/www.fda.gov\/drugs\/postmarketing-requirements-and-commitments-introduction\/postmarketing-requirements-and-commitments-frequently-asked-questions-faq [Accessed 13 Jun 2025]."},{"key":"2026072406050713000_5.1.e002307.20","unstructured":"U.S. Food and Drug Administration . Drug safety-related labeling changes (SRLC) database overview: updates to safety information in fda-approved prescription drug labeling. FDA; 2024. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/drug-safety-related-labeling-changes-srlc-database-overview-updates-safety-information-fda-approved [Accessed 13 Jun 2025]."},{"key":"2026072406050713000_5.1.e002307.21","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5725","article-title":"A descriptive analysis of postmarketing requirement studies and clinical trials","volume":"33","author":"Choi","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026072406050713000_5.1.e002307.22","unstructured":"U.S. Food and Drug Administration . Approved risk evaluation and mitigation strategies (REMS). Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm [Accessed 13 Jun 2025]."},{"key":"2026072406050713000_5.1.e002307.23","unstructured":"Drug Safety Communications . FDA. 2025. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/drug-safety-communications"},{"key":"2026072406050713000_5.1.e002307.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2026072406050713000_5.1.e002307.25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.30486","article-title":"Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies","volume":"7","author":"Mooghali","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026072406050713000_5.1.e002307.26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jamainternmed.2022.4226","article-title":"Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016","volume":"182","author":"Brown","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2026072406050713000_5.1.e002307.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k2031","article-title":"Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis","volume":"361","author":"Wallach","year":"2018","journal-title":"BMJ"},{"key":"2026072406050713000_5.1.e002307.28","unstructured":"Post-authorisation measures: questions and answers . European Medicines Agency (EMA). 2000. Available: https:\/\/www.ema.europa.eu\/en\/pharmacovigilance-post-authorisation\/post-authorisation-measures-questions-and-answers [Accessed 24 Oct 2025]."},{"key":"2026072406050713000_5.1.e002307.29","unstructured":"European Medicines Agency (EMA) . Post-authorisation safety studies (PASS). 2015. Available: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/post-authorisation-safety-studies-pass"},{"key":"2026072406050713000_5.1.e002307.30","unstructured":"European Medicines Agency (EMA) . Post-authorisation efficacy studies: questions and answers. 2015. Available: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/post-authorisation-efficacy-studies-questions-answers"},{"key":"2026072406050713000_5.1.e002307.31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/cpt.3410","article-title":"Comparative Analysis of Post-Authorization Measures for Advanced Medicinal Products Authorized in the European Union and in the United States of America Between 2009 and 2023","volume":"117","author":"Mandslay","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"2026072406050713000_5.1.e002307.32","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12940"},{"key":"2026072406050713000_5.1.e002307.33","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/cpt.2679","article-title":"Post-Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004-2014","volume":"112","author":"Cherla","year":"2022","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2025-002307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:05:17Z","timestamp":1784898317000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2025-002307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,24]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjmed-2025-002307"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2025-002307","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}